Now Playing
Opinion|Videos|June 27, 2024
Biomarker Testing and Guideline-Recommended Care in mNSCLC
Mark Socinski, MD, introduces a panel of medical experts as they kick off a discussion surrounding biomarker testing and guideline recommendations in the metastatic non-small cell lung cancer treatment landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the current NCCN guideline recommendations regarding molecular/genetic testing (NGS, etc.) for newly diagnosed mNSCLC patients?
- Do the NCCN guideline recommendations for molecular/genetic testing and biomarker evaluation differ between squamous and non-squamous non-small cell lung cancer? If so, how, and why?
- What is the rationale and clinical utility of comprehensive biomarker testing in this setting?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Congress Unveils Massive Funding Bill to Avert Shutdown
2
ctDNA Positivity Associated With Worse Survival, Higher Recurrence Risk in Patients With NSCLC
3
Novel CLL Therapies Prompt New Treatment Considerations
4
Early Data Show Feasibility of in Vivo CAR T Therapy in Multiple Myeloma
5
